LEIDEN, Netherlands– Ncardia, a provider of stem cell–based solutions for drug discovery and safety assessment, announced Tuesday the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys.
The new cell platform provides researchers with a scalable, ethical, and translational tool for cross-species cardiac studies, addressing the need for physiologically relevant in vitro models that reduce reliance on live animals in preclinical testing. The development also aligns with the U.S. Food and Drug Administration’s updated guidance to minimize animal use in drug safety studies.
Ncyte® NHP-C vCardiomyocytes are designed to mimic human cardiac electrophysiology and pharmacology, offering a high-purity, functional alternative for safety screening. The cells enable pharmaceutical and biotech companies to conduct more predictive cardiotoxicity assessments, lower risk in drug development, and advance safer therapies.
“As the only iPSC-derived NHP ventricular cardiomyocytes on the market, Ncyte® NHP-C vCardiomyocytes set a new standard for translational cardiovascular research,” said Jeroen de Groot, divisional chief executive of Ncardia. “They give researchers the ability to perform direct cross-species comparisons in vitro, improve cardiotoxicity risk assessment and meet the FDA’s evolving expectations around reducing the use of live non-human primates in safety testing.”
